In the hunt for new therapeutics for cancer and infectious diseases, lasso peptides prove to be a catch. Their knot-like ...
Viltrox has announced a new standard prime with a fast F1.4 aperture for Sony E and Nikon Z mount full-frame cameras.
Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback